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Products secreted from nerve terminals can have profound
effects on the phenotype and functioning of T cells. One
such product, vasoactive intestinal peptide (VIP) is a small
neuroendocrine peptide hormone with potent anti-
inflammatory activities. Binding to either of its type B G
protein coupled receptors VPAC1 and VPAC2 initiates a
signaling cascade that ultimately inhibits the secretion of
pro-inflammatory cytokines and reduces proliferative
capacity via inhibition of NF-B[1]. The anti-inflammatory
effects of VIP signaling in immune cells have demon-
strated to be inhibitable with the use of one of several
small molecule antagonists. VIPhyb is a hybrid peptide
antagonist consisting of the VIP peptide with a six amino
acid substitution at the N-terminus. We demonstrate here
that subcutaneous administration of small doses of VIPhyb
enhanced the autologous T cell response in mice bearing
C1498 acute myeloid leukemia. Secretion of both IFN-g
and TNF-a was significantly increased in VIPhyb-treated
mice. Additionally, the frequency of PD-1-expressing CD4
and CD8 T cells was significantly lower in mice treated
with the VIP antagonist. This was determined to be of
relevance in this model as PD-L1 was found to be induci-
ble on C1498 cells. This expression was not affected by
VIPhyb treatment. Each of these effects contributed to a
reduction in tumor burden in VIPhyb-treated mice as evi-
denced by bioluminescent imaging. No direct cytotoxic
effect of VIPhyb on the tumor cells themselves was
observed despite the expression of VPAC2. Overall survi-
val of mice that received 1, 3, or 7 doses was significantly
higher than vehicle-treated controls as a result of
enhanced immunological function. Importantly, VIPhyb-
treated survivors were found to be resistant to further
tumor development following re-challenge with C1498
cells. This observation highlights a contribution of VIP sig-
naling blockade in the development of anti-leukemia
T cell memory. The data heretofore described highlight
the contribution of VIP to the inhibition of anti-leukemia
T cell responses and thus present rationale for considering
this pathway in the design of therapeutic strategies for
AML. VIP signaling blockade is thus a promising candi-
date for the enhancement of immunotherapies that seek
to strengthen the anti-leukemia T cell response.
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